VivoSeq
Metabolic & Endocrine

Familial Hyperlipidemia

5

Pipeline Programs

0

Active Trials

4

Companies Involved

Familial Hyperlipidemia is an early-stage landscape with 5 programs across 4 companies. The most active players are Sanofi, Pfizer, AbbVie. 5 therapies are approved.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)